Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Lepu ScienTech to acquire stake in Minwei Biotechnology

PRIVATEAug 22, 2026about 3 hours ago

Acquiring Company

Lepu ScienTech Medical Technology (Shanghai) Ltd

Acquired Company

Shanghai Minwei Biotechnology Ltd

ShanghaiHealth CareMedical

Description

Lepu ScienTech Medical Technology is acquiring a 54.2384% equity stake in Shanghai Minwei Biotechnology for RMB1.09 billion. This transaction is considered a major and connected deal requiring shareholder approval. The acquisition is part of Lepu's strategy to expand its role in biotechnology. Regulatory scrutiny is expected due to the connection with the controlling shareholder.

Company Information

Company

Lepu ScienTech Medical Technology (Shanghai) Ltd

Location

Shanghai, China

About

Lepu ScienTech Medical Technology is a Hong Kong-listed group engaged in medical technologies. The company focuses on innovation and expansion in various health sectors. It aims to enhance healthcare solutions through strategic investments and acquisitions.

Don't miss Lepu ScienTech Medical Technology (Shanghai) Ltd's next move

Get an email the moment Lepu ScienTech Medical Technology (Shanghai) Ltd makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Lepu ScienTech Medical Technology (Shanghai) Ltd's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Shanghai Minwei Biotechnology Ltd?

Shanghai Minwei Biotechnology Ltd was acquired by Lepu ScienTech Medical Technology (Shanghai) Ltd, based in Shanghai. The deal was reported on August 22, 2026. Lepu ScienTech Medical Technology is a Hong Kong-listed group engaged in medical technologies. The company focuses on innovation and expansion in various health sectors. Lepu ScienTech Medical Technology (Shanghai) Ltd is privately held and operates in Health Care.

When did Lepu ScienTech Medical Technology (Shanghai) Ltd acquire Shanghai Minwei Biotechnology Ltd?

Lepu ScienTech Medical Technology (Shanghai) Ltd's acquisition of Shanghai Minwei Biotechnology Ltd was reported on August 22, 2026. Lepu ScienTech Medical Technology is acquiring a 54.2384% equity stake in Shanghai Minwei Biotechnology for RMB1.09 billion. This transaction is considered a major and connected deal requiring shareholder approval. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Shanghai Minwei Biotechnology Ltd do?

Shanghai Minwei Biotechnology Ltd is the company acquired in this transaction. It is privately held.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.